Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) fell 5.9% during mid-day trading on Thursday following insider selling activity. The company traded as low as $56.44 and last traded at $56.48. 317,027 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 581,232 shares. The stock had previously […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) and Hypera (OTCMKTS:HYPMY – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Analyst Recommendations This is a summary of current recommendations and price […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 3,580,000 shares, a decline of 5.8% from the April 30th total of 3,800,000 shares. Based on an average trading volume of 598,200 shares, the […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its price target lifted by Barclays from $44.00 to $46.00 in a research report sent to investors on Tuesday, The Fly reports. A number of other analysts have also issued reports on the company. Stifel Nicolaus boosted their price objective on Blueprint Medicines from $80.00 to $84.00 in […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its target price boosted by Guggenheim from $78.00 to $82.00 in a report published on Tuesday, The Fly reports. A number of other equities analysts have also recently weighed in on the stock. JMP Securities reaffirmed a market outperform rating and set a $114.00 price target on shares […]